Taprenepag

SKU: orb1304459

Description

Taprenepag (CP-544326) is a potent and selective EP2 prostaglandin receptor agonist with an EC50 of 2.8 nM. It has been investigated in clinical trials for lowering intraocular pressure in ocular hypertension and open-angle glaucoma, supported by both in vitro receptor studies and in vivo pharmacological research.

Research Area

Immunology & Inflammation, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 752187-80-7
• MW: 478.52
• Purity: 99.32%
• Formula: C₂₄H₂₂N₄O₅S
• SMILES: OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1
• Target: Prostaglandin Receptor
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.18 mM);DMSO:55 mg/mL (114.94 mM)

Bioactivity

• Target IC50:
  Prostaglandin E2:2.8 nM(EC50)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

cells, CP544326, CP-544326, CP 544326, cAMP, inhibit, intraocular, Inhibitor, levels, HEK293, Prostaglandin Receptor, ProstaglandinReceptor, pressure, PGE2, Taprenepag

Compound Identifiers

PubChem CID

18376177